Ansamycins exert their effects by binding heat shock protein 90 (Hsp90) and targeting important signalling molecules for degradation via the proteasome pathway. We wanted to study the effect of geldanamycin (GA) and its derivative 17-allylamino-17-demethoxygeldanamycin (17-AAG) on glioblastoma cell lines. We show that these cells are growth inhibited by ansamycins by being arrested in G 2 / M and, subsequently, cells undergo apoptosis. The protein levels of cell division cycle 2 (cdc2) kinase and cell division cycle 25c (cdc25c) were downregulated upon GA and 17-AAG treatment and cdc2 kinase activity was inhibited. However, other proteins involved in the G 2 /M checkpoint were not affected. The cdc2 and cdc25c mRNA levels did not show significant differences upon ansamycin treatment, but the stability of cdc2 protein was reduced. The association of cdc2 and cdc25c with p50 cdc37 , an Hsp90 cochaperone, decreased, but the interaction of cdc2 and cdc25c with the Hsp70 co-chaperone increased after ansamycin treatment. Proteasome inhibitors were able to rescue the cdc2 downregulation, but not the cdc25c reduction. However, calpain inhibitors were able to rescue the cdc25c downregulation, suggesting that cdc25c is proteolysed by calpains in the presence of ansamycins, and not by the proteasome. We conclude that ansamycins downregulate cdc2 and cdc25c by two different mechanisms.
Introduction
Glioblastoma is the most common, aggressive and difficult to treat primary brain tumour. Current therapy includes surgery, radiation and chemotherapy. However, these tumours show resistance to chemotherapy and radiation (Stupp et al., 2006) . We were interested in elucidating strategies to enhance cell death in glioblastoma. We have used heat shock protein (Hsp90) inhibitors to determine their effects on glioblastoma cell lines. Hsp90 is a ubiquitously expressed molecular chaperone involved in the folding, maturation, activation and assembly of various proteins such as mediators of signal transduction, cell cycle control and transcriptional regulation (Kamal et al., 2004) . Ansamycins are antibiotics that bind to a conserved pocket in the NH2-terminal adenosine triphosphate (ATP)-binding domain of Hsp90, inhibiting its activity. Ansamycins were first discovered by causing degradation of the tyrosine kinase src (Whitesell et al., 1994) , and they were later found to cause degradation of other kinases involved in mitogenic responses such as HER2/Neu (Miller et al., 1994) , raf (Schulte et al., 1995) and mutated p53 , which make them very attractive as potential anti-tumour agents. Hsp90 participates in two multichaperoning complexes with opposing activities. When ATP is bound, the complex, which includes p23 and p50 cdc37 , binds to and stabilizes Hsp90 client proteins. However, when ADP is bound, other assembling factors, such as p60
Hop and Hsp70, take part in the complex and the Hsp90 client proteins are targeted to degradation, probably by the proteasome. Hsp90 inhibitors such as geldanamycin (GA) force the chaperone to adopt this conformation (Neckers, 2002) .
Ansamycins have been shown to cause cell cycle arrest (McIlwrath et al., 1996; Kim et al., 1999; Srethapakdi et al., 2000; Hostein et al., 2001; de Ca´rcer, 2004; Georgakis et al., 2006a) and apoptosis (Munster et al., 2002; Demidenko et al., 2006; Georgakis et al., 2006b) . Targeting the cell cycle machinery is a novel strategy used in cancer therapeutics. Deregulation of the cell cycle and evasion of apoptosis are considered hallmarks of cancer. Hsp90 inhibitors can induce cell cycle arrest by downregulating important signalling molecules such as HER2, raf or Akt (Kamal et al., 2004) and subsequently cell cycle arrest can lead to apoptosis.
In this report, we set out to determine the effects of the naturally occurring benzoquinone GA, a type of ansamycin, and its derivative 17-allylamino-17-demethoxygeldanamycin (17-AAG) on glioblastoma cell lines. Our data indicate that GA and 17-AAG inhibit cell proliferation, induce accumulation of cells in the G 2 / M phase of the cell cycle and apoptosis. Proteins involved in the G 2 /M checkpoint such as cell division cycle 2 (cdc2) and cell division cycle 25c (cdc25c) are downregulated by ansamycins. However, their mechanism of regulation is different. Cdc2 protein levels can be rescued with proteasome inhibitors, indicating that cdc2 is targeted to degradation via the proteasome pathway; however, cdc25c protein levels can be rescued with calpain inhibitors.
Results
GA and 17-AAG inhibit cell growth and induce apoptosis U87, T98, A172 and LN229 glioblastoma cell lines were growth inhibited with GA and 17-AAG (Figure 1a and b). The IC 50 of growth inhibition of GA is 110 nM for U87 cells, 98 nM for A172 cells, 180 nM for T98 cells and 58 nM for LN229 cells. The IC 50 of growth inhibition of 17-AAG is 115 nM for U87 cells, 122 nM for A172 cells, 78 nM for T98 cells and 64 nM for LN229. T98 cells were more sensitive to 17-AAG than to GA. This growth inhibition was accompanied with an increase in apoptotic cells, as determined by flow cytometry (Figure 1c ).
Ansamycins effect on cell cycle distribution
We performed cell cycle analyses and found that glioblastoma cells accumulated in the G 2 /M phase of the cell cycle upon GA treatment (Figure 1d ). Similar results were found with 17-AAG (data not shown). Furthermore, U87 were synchronized with aphidicolin at the G 1 /S boundary and we found that the G 2 /M arrest was sustained after release in GA in treated cells (Figure 1e ).
GA and 17-AAG downregulate cdc2 and cdc25c protein levels In order to determine the molecular mechanism by which GA and 17-AAG causes a G 2 /M arrest, we analysed the steady-state levels of proteins involved in the G 2 /M checkpoint and found that cdc2 and the phosphatase cdc25c were downregulated upon GA and 17-AAG treatment in all the glioblastoma cell lines analysed (Figure 2a and b; data not shown). However, cyclin B 1 , cyclin A and cdc25b were not affected by the drug (Figure 2a) . We observed that the downregulation of both cdc2 and cdc25c was sustained over time (Figure 2b) and that the levels of cdc2 decreased faster than the levels of cdc25c (Figure 2c and d) . The downregulation of cdc2 and cdc25c by GA and 17-AAG was dose dependent (data not shown).
Ansamycins affect cdc2 kinase activity
We analysed the steady-sate levels of proteins involved in the G 2 /M checkpoint after syncronizing U87 cells with aphidicolin, and found that cdc25c protein decreased at a faster rate than cdc2 protein (Figure 3a) . In order to further characterize the effects of GA on cdc2 kinase activity, we performed kinase assays and found that the kinase activity of cdc2 also decreased in synchronized cells (Figure 3b ), paralleling the downregulation of cdc2 and cdc25c, and also the accumulation of cells in G 2 /M (Figure 1e ). The cdc2 kinase activity decreased in a time-dependent manner after GA treatment in the four glioblastoma cell lines (Figure 3c ).
Ansamycins effect on cdc25c and cdc2 mRNA levels In order to determine the mechanism by which GA was able to downregulate cdc25c and cdc2, we performed real time quantitative reverse transcription (RT)-PCR analyses after 8 and 24 h of GA treatment and found that there were no significant changes in mRNA levels upon such treatments (Figure 4) .
Ansamycins affect the half-life of cdc2
Ansamycins are able to induce downregulation of proteins by increasing their degradation. We wanted to confirm this hypothesis by studying the half-life of cdc2 in the presence of cycloheximide (CHX). We pretreated A172 cells for 4 h with GA followed by treatment with CHX in the presence or absence of GA for different times. We found that the half-life of cdc2 decreased dramatically in the presence of GA ( Figure 5 ).
Cdc2 and cdc25c as Hsp90 client proteins
In order to determine whether both cdc2 and cdc25c were client proteins of Hsp90, we studied the association of these proteins by immunoprecipitation, followed by western blot analyses. We found that cdc2 and cdc25c were in a complex with Hsp90 and that this association increased after GA treatment (Figure 6 ), suggesting that the association of both cdc2 and cdc25c with Hsp90 is required for maintaining their stability. However, the interaction of these proteins with the co-chaperone p50 cdc37 decreased after GA treatment ( Figure 6 ). The association of both cdc2 and cdc25c with the cochaperone Hsp70 augmented after GA treatment, indicating that these Hsp90 clients are susceptible for degradation in this state of Hsp90-Hsp70 ADP-bound complex (Neckers, 2002) .
Proteasome inhibitors are able to rescue cdc2 protein levels after GA treatment Hsp90 client proteins are targeted for degradation via the ubiquitin-proteasome pathway when associated with the ADP-bound complex. We wanted to confirm this hypothesis by using different proteasome inhibitors (lactacystin, MG-132, proteasome inhibitor I (PSI) and epoxomicin) in the presence of GA. We found that indeed, the cdc2 protein levels were rescued, at least partially, with four different proteasome inhibitors ( Figure 7) . However, the levels of cdc25c protein decreased even more, indicating a different mechanism of degradation.
Calpain inhibitors are able to rescue cdc25c protein levels after GA treatment We treated glioblastoma cells with different protease inhibitors in the presence of ansamycins to determine its and 24 h and subjected to western blot analysis using the antibodies indicated. In addition, A172, T98 and LN229 cells were treated with DMSO or 500 nM GA for the times indicated and levels of cdc2, cdc25c and actin were determined by western blot. (b) U87, A172, T98 and LN229 cells were treated with DMSO or 500 nM GA for the times indicated and levels of cdc2, cdc25c and actin were determined by western blot. mechanism of degradation. A caspase inhibitor (Z-VAD-FMK), a serine protease inhibitor (AEBSF) and an inhibitor of lysosomal function (NH 4 Cl) had no effect on either cdc2 or cdc25c protein levels ( Figure 7) . However, inhibitors of calpains such as calpeptin, PD150606 (PD) and EST were able to abrogate the GA downregulation of cdc25c protein caused by ansamycin treatment, but they did not alter the downregulation of cdc2 ( Figure 7 ).
Discussion
Glioblastoma is a very aggressive and difficult to treat type of tumour. In this report, we have studied the effects of ansamycins, such as GA and 17-AAG on glioblastoma cell lines. We have found that both GA and 17-AAG were able to inhibit cell proliferation with IC 50 ranging from 58 to 180 nM (Figure 1a and b) . Glioblastoma cell lines underwent apoptosis within 24 h of treatment, as detected by flow cytometry (Figure 1c ) and Hoechst staining (data not shown). Furthermore, cell cycle analyses by flow cytometry revealed accumulation of cells in the G 2 /M phase of the cell cycle after 24 or 48 h of GA treatment (Figure 1d ). This G 2 /M arrest was sustained in synchronized U87 cells (Figure 1e ). It has been shown that GA can induce mitotic catastrophe and apoptosis in T98 cells (Nomura et al., 2004) . We have confirmed these data but we were able to observe accumulation of mitotic cells only in A172 and T98 cells (data not shown). Therefore, we investigated the steadystate levels of proteins involved in the G 2 /M checkpoint and found that cdc2 and cdc25c protein levels were downregulated after GA and 17-AAG treatment in a time-and dose-dependent manner, in both asynchronous and synchronized cell populations (Figures 2 and  3) . Cdc2 (or cdk1) is the cyclin-dependent kinase responsible for the entry and exit from G 2 and mitosis. It forms a complex with cyclin B 1 or cyclin A. It can be inactivated by wee-1 and myt-1 when it is phosphorylated in T15. The phosphatase responsible for removing this phosphate group is cdc25b or c (Nigg, 2001) . The downregulation of both cdc25c and cdc2 causes inactivation of cdc2 kinase activity. In fact, we were able to detect loss of kinase activity in a time-dependent manner in asynchronous and synchronized glioblastoma cell populations (Figure 3) . It has been suggested that inhibition of Hsp90 function by ansamycins target Hsp90 client proteins for degradation. We wanted to determine the mechanism of downregulation of both cdc2 and cdc25c. We performed real time quantitative RT-PCR analyses of cdc2 and cdc25c in the four glioblastoma cell lines treated with GA. We did not find differences significant enough to explain the reduction observed at the protein level of either cdc2 or cdc25c (Figure 4) . Then, we wanted to determine the half-life of cdc2 in the presence of GA and we observed that indeed, GA was able to dramatically reduce the stability of cdc2 protein within 15 min of CHX treatment (Figure 5 ), indicating that, as expected, ansamycins had an effect on the degradation of cdc2 protein. Unfortunately, we were unable to determine the half-life of cdc25c by using this approach. To demonstrate whether cdc2 and cdc25c were Hsp90 client proteins, we immunoprecipitated either cdc2 or cdc25c with specific antibodies and analysed by western blot their interaction with Hsp90. We found that the Downregulation of cdc2 and cdc25c by ansamycins P García-Morales et al association of both cdc2 and cdc25c proteins with Hsp90 increased over time after GA treatment in A172 cells ( Figure 6 ) and other glioblastoma cell lines as well (data not shown). We also determined which conformation state of the Hsp90 complex was associated with both cdc2 and cdc25c proteins. We found that the interaction of either cdc2 or cdc25c with p50 cdc37 decreased after GA treatment ( Figure 6 ) and that conversely, the association of cdc2 and cdc25c with Hsp70 in glioblastoma cells increased over time after GA treatment ( Figure 6 ). We conclude from these experiments that cdc2 and cdc25c are Hsp90 client proteins and that ansamycin treatment alters the composition of the chaperone complexes associated with either cdc2 or cdc25c, as it has been demonstrated with oncoproteins such as bcr-abl, src , Akt , or mutated B-raf (da Rocha et al., 2005; Grbovic et al., 2006) . After GA treatment, the multichaperone complex tends to adopt the ADP-bound conformation, which may target cdc2 and cdc25c proteins for degradation, presumably via the proteasome. We have employed proteasome inhibitors to test this hypothesis and found that, indeed, four different proteasome inhibitors were able to abrogate the downregulation of cdc2 protein caused by ansamycins ( Figure 7) . However, the levels of cdc25c decreased even more after these treatments. We used a general caspase inhibitor (Z-VAD-FMK), a serine protease inhibitor (AEBSF) and an inhibitor of lysosomal function (NH 4 Cl) and neither of these agents had an effect on the cdc2 or the cdc25c protein downregulation provoked by GA ( Figure 7 ). Next, we tested the effect of three different calpain inhibitors and found that whereas they had no effect on cdc2 protein downregulation, they were able to, at least partially, abrogate the cdc25c protein downregulation due to GA treatment (Figure 7 ). Calpains are a family of calcium-activated, non-lysosomal cystein endopeptidases expressed in all mammalian cells. Calpains have many substrates, including some phosphatases (Sorimachi et al., 1997) . We hypothesize that cdc25c may also be a substrate of calpains. This is the first report showing an effect of ansamycins mediated by calpains. However, the mechanism by which calpains induce degradation of cdc25c needs further investigation. It has been shown that Hsp90 has a specific cleavage site for calpain (Bellocq et al., 1999) .
We speculate that calpain inhibitors may abrogate the Effect of GA on cdc2 protein half-life. A172 cells were pretreated with 500 nM GA or left untreated for 4 h, and CHX (10 mg/ml) was added in the presence or absence of GA for the times indicated. Protein bands were quantified and cdc2 protein bands were normalized to actin protein bands, represented as the average of three separate experiments and referred as percentage of control. Error bars represent the s.e.m. CHX, cycloheximide; GA, geldanamycin.
Hsp90 downregulation due to calpain and, therefore, rescue the degradation of cdc25c caused by Hsp90 inhibition.
A recent report has shown that GA and 17-AAG can cause a G 2 /M arrest that is associated with reduction of cdc25c and cdc2 in lung cancer cell lines (Senju et al., 2006) . However, the authors did not study in detail the mechanism of downregulation of both cdc25c and cdc2 in these cell lines. The results presented herein show that ansamycins are able to inhibit cell proliferation, induce G 2 /M arrest and apoptosis in different glioblastoma cell lines. This G 2 /M arrest is due to downregulation of cdc25c and cdc2 proteins and a subsequent loss in cdc2 kinase activity. Ansamycin treatment affects the stability of these proteins, inducing their degradation. Both cdc2 and cdc25c are Hsp90 client proteins and they are Effect of proteasome and diverse protease inhibitors. U87 cells were nontreated or treated with proteasome inhibitors: 10 mM LAC, 10 mM MG132, 25 mM PSI and 0.5 mM epo, with 25 mM Z-VAD-FMK (VAD), 100 mM AEBSF, 20 mM NH 4 Cl, or with calpain inhibitors: 30 mM CALP, 100 mM PD150606 (PD) and 40 mM EST for 30 min before the addition of DMSO or 500 nM GA for 24 h. The levels of cdc25c and cdc2 were analysed by western blot. CALP, calpeptin; DMSO, dimethylsulphoxide; epo, epoxomicine; GA, geldanamycin; LAC, lactacystin; PSI, proteasome inhibitor I.
associated with the ADP-bound form of the complex in the presence of ansamycins, which target these proteins for degradation. Cdc2 is targeted to the proteasome, as demonstrated with the abrogation of this effect with different proteasome inhibitors. However, cdc25c seems to be degraded by calpains. GA derivatives such as 17-AAG and 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG) are undergoing clinical trials of different kind of tumours, showing promising results (Drysdale et al., 2006; Sharp and Workman, 2006; Xiao et al., 2006) . Based on our results, we can conclude that ansamycins may have a potential to be used in the clinic for the treatment of glioblastomas, either as single agents or in combination with other antitumour agents or radiotherapy.
Materials and methods

Reagents
GA and 17-AAG were purchased from Stressgen (Victoria, BC, Canada) and dissolved in dimethylsulphoxide (DMSO). Proteasome inhibitors (lactacystin, MG132, PSI, epoxomicin), diverse protease inhibitors (Z-VAD-FMK, AESBF) and calpain inhibitors (calpeptin, PD150606, EST) were purchased from Calbiochem (San Diego, CA, USA). Aphidicolin, propidium iodide and CHX were purchased from SigmaAldrich (St Louis, MO, USA).
Cell culture
The human glioblastoma cell lines U87-MG (U87), A172, T98G (T98) and LN229 were obtained from the American Type Culture Collection (Manassas, VA, USA). Cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10% heat-inactivated fetal bovine serum, 2 mM glutamine, 1 mM sodium pyruvate, 50 U/ml of penicillin and 50 mg/ml streptomycin and incubated at 371C in a humified 5% CO 2 /air atmosphere.
Cell proliferation assays
Cells were plated in 96-well plates at a density of 2000-3000 cells per well, depending on the cell line, treated with vehicle (DMSO) or different doses of GA or 17-AAG using six wells per treatment for 3 days, washed with phosphate-buffered saline (PBS), fixed with 4% formaldehyde and stained with 0.05% crystal violet for 30 min at room temperature. Cells were then washed three times with deionized water, and the wells were completely dried at 371C for at least 30 min. Cells were lysed with 0.1 M HCl and absorbance was determined at 620 nm in a microplate reader (Anthos 2001 Labtec Instruments GmbH, Wals, Austria). Viability of cells was monitored using the trypan blue dye-exclusion method.
Flow cytometry
Cells were plated in 100-mm dishes and treated with GA or 17-AAG for particular times. Cells were trypsinized, washed with PBS, fixed with 75% cold ethanol at À201C for at least 1 h, treated with 0.5% Triton X-100 and 0.05% RNaseA in PBS for 30 min, stained with propidium iodide and analysed using an Epics XL flow cytometer (Beckman Coulter Co., Miami, FL, USA) to determine cell cycle distribution of DNA content. For synchrony experiments, cells were treated with 1 mg/ml aphidicolin (G 1 /S arrest) for 22 h, washed with PBS and released into either vehicle (DMSO) or GA before analysing their DNA content.
Western blot analysis Cells were plated for different times, treated with DMSO, GA, or 17-AAG, lysed in a lysis buffer containing 50 mM Tris pH 7.4, 1% NP40, 150 mM NaCl, 40 mM NaF, 1 mM Na 3 VO 4 , 1 mM PMSF and 10 ml/ml of protease inhibitor cocktail (Sigma-Aldrich). Protein determinations were performed by the Bradford method (Bio-Rad, Richmond, CA, USA). Then, 50-80 mg of protein from each lysate were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), transferred to nitrocellulose membranes, incubated with primary antibodies against cyclin B 1 , cyclin A, cdc2, cdc25c, cdc25b, Hsp90, p50 cdc37 , Hsp70 from Santa Cruz Biotechnology (Santa Cruz, CA, USA), or actin (SigmaAldrich), incubated with horseradish peroxidase-linked secondary antibodies and proteins were detected by the ECL method (Amersham International, Buckinghamshire, UK). Densitometric analyses were performed using the SigmaGel gel analysis software (Jandel Scientific, Chicago, IL, USA).
Immunoprecipitation
Cells were treated, harvested and lysed as above. Then, 500-800 mg of protein were incubated with antibodies against cdc2 or cdc25c (Santa Cruz Biotechnology) or a control IgG (Sigma-Aldrich), and rotated end over end overnight at 41C, followed by incubation for 1 h at 41C with protein G-Sepharose beads (Pierce Chemical Co., Rockford, IL, USA). Beads were washed four times with lysis buffer and resuspended in SDS-PAGE sample buffer. Proteins were eluted by boiling the beads and were subjected to SDS-PAGE electrophoresis, transferred to nitrocellulose membranes, incubated with primary antibodies, washed, incubated with secondary antibodies, incubated with ECL reagents and exposed to autoradiography.
In vitro cdc2 kinase assays Cells were treated as above, lysed in a buffer containing 50 mM Tris pH 7.5, 0.5 M NaCl, 5 mM EDTA, 2 mM EGTA, 0.01% Brij 35, 25 mM b-glycerol phosphate, 1 mM PMSF and 10 ml/ml of protease inhibitor cocktail (Sigma-Aldrich), and 100 mg of protein were incubated with HCK gel suspension (MBL, Woburn, MA, USA). Then, samples were processed with the MESACUP cdc2 kinase assay kit (MBL) according to the manufacturer's instructions and absorbance was detected at 492 nm using a microplate reader (Anthos 2001 Labtec Instruments).
Real time quantitative RT-PCR
To determine the level of cdc2 and cdc25c mRNA, total RNA from nontreated or GA-treated cells were isolated using the TRI reagent (Sigma-Aldrich). To eliminate potential DNA contamination, total RNA was treated with RQ1 DNase (Promega Corp., Madison, WI, USA) for 30 min at 371C, followed by 2 min at 941C. Reverse transcription of 1 mg RNA was performed using the TaqMan Reverse Transcription Reagents kit (Applied Biosystems, Foster City, CA, USA) according to the manufacturer's instructions. Real time quantitative PCR was performed to amplify 15 ng of cDNA using the ABI PRISM 7700 Sequence Detector System (Applied Biosystems). Primers and probe to amplify cdc2 (Hs00364293_m1) and cdc25c (Hs00156411_m1) were designed using Primer Express software (Applied Biosystems). Taqman probes were labelled with 6-FAM in 5 0 end as the reporter dye, and with a nonfluorescent quencher dye in 3 0 end. Glyceraldehyde-3-phosphate-dehydrogenase (GAPDH) was used as endogenous reference in multiplex PCR. Primers and Taqman probe for GAPDH were purchased from Applied Biosystems. GAPDH Taqman probe was labelled with VIC in 5 0 end as the reporter dye and with a non-fluorescent quencher dye in 3 0 end. Cdc2 and cdc25c mRNA relative gene expression in glioblastoma cell lines was calculated by the comparative Ct method referred to the GAPDH mRNA housekeeping gene expression.
